Atara Biotherapeutics (ATRA) Gross Profit (2022 - 2026)

Atara Biotherapeutics' Gross Profit history runs 5 years deep, the most recent figure standing at $392000.0 for Q1 2026.

• Quarterly Gross Profit fell 99.5% year-over-year to $392000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 86.12% YoY) and the FY2025 annual result came in at $99.6 million, down 7.76% from the prior year.
• Gross Profit was $392000.0 for Q1 2026 at Atara Biotherapeutics, down from $1.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $77.7 million in Q1 2025 and bottomed at -$6.2 million in Q4 2023.
• A 5-year average of $16.1 million and a median of $3.9 million in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit tumbled 448.0% — and 2024, when it jumped 5576.97%.
• Atara Biotherapeutics' Gross Profit stood at $1.8 million in 2022, then tumbled by 448.0% to -$6.2 million in 2023, then surged by 520.71% to $26.0 million in 2024, then plunged by 94.26% to $1.5 million in 2025, then sank by 73.71% to $392000.0 in 2026.
• Business Quant data shows ATRA's Gross Profit at $392000.0 in Q1 2026, $1.5 million in Q4 2025, and $3.3 million in Q3 2025.